Monitoring lysosomal dynamics in real-time, especially in vivo, poses significant challenges due to the complex and dynamic nature of cellular environments. It is extremely important to construct fluorescent probes with high stability for imaging lysosomes to minimize interference from other cellular components, in order to ensure prolonged imaging. A fluorescent probe (PDB) has been proposed for targeting lysosomes, which was less affected to changes in the cellular microenvironment (such as pH, viscosity and polarity). PDB can be easily prepared by 4'-piperazinoacetophenone and 2-(4-diethylamino)-2-hydroxybenzoyl) benzoicacid, containing a piperazine group for labeling and imaging lysosomes and the high pKa value (∼9.35) allowed PDB to efficiently track lysosomes. The emission wavelength of PDB in aqueous solution was 634 nm (λ_ex = 572 nm, Ф_f = 0.11). The dynamic process of lysosome induced by starvation and rapamycin was successfully explored by fluorescence imaging. Compared with the commercially available Lyso-Tracker green, the high photostability fluorescent probe can ensure 3D high-fidelity tracking and resist photobleaching. Therefore, PDB, unaffected by the cell microenvironment, successfully achieved long-term tracking of lysosomal movement, even enabling imaging in tumor-bearing mice over 11 days. The strong fluorescence signal, high stability, and long-term tracking capability indicate that PDB has tremendous potential in monitoring biological processes.

01 Oct 2024·Journal of Vascular Surgery

Popliteal-distal bypass affords better limb salvage than tibial angioplasty for chronic limb-threatening ischemia

Article

Author: Sidawy, Anton ; Recarey, Melina ; Nguyen, Bao-Ngoc ; Rodriguez, Stephanie ; Amdur, Richard ; Peshel, Emanuela ; Li, Renxi ; Lala, Salim

OBJECTIVEChronic limb-threatening ischemia (CLTI) due to isolated tibial occlusive disease is treated by either popliteal-distal bypass (PDB) or tibial angioplasty (TA), although there is limited data directly comparing efficacy and outcomes between these two treatment modalities. This study compares 30-day mortality and major adverse limb events following infrapopliteal bypass and TA in patients with CLTI.METHODSPatients who underwent PDB for CLTI were extracted from American College of Surgeons National Surgical Quality Improvement Program targeted lower extremity open database, whereas patient with CLTI who underwent isolated TA were identified in the targeted lower extremity endovascular database. Any case with more proximal angioplasty such as femoral/popliteal/iliac was excluded. The time interval was 2011 through 2022. The two groups were comparable in demographics, and preoperative comorbidities were obtained using propensity matching. Mortality, systemic complications, and major adverse limb events were measured. Multivariable logistic regression was used for data analysis. To obtain granular data on the angiographic characteristics of patients undergoing PDB or TA, The George Washington University institutional data from 2014 to 2019 was used as a supplement to the database.RESULTSThere were 1947 and 3423 cases identified in the bypass and endovascular groups, respectively. After propensity matching for all preoperative variables, 1747 cases remained in each group. Although bypass was associated with higher major adverse cardiovascular events, pulmonary, renal, and wound complications, bypass had significantly better 30-day limb salvage when compared with TA (major amputation rate, 3.32% vs 6.12%; P < .01). Institutional data identified 69 patients with CLTI due to isolated tibial occlusive disease; 25 (36.2%) underwent PDB and 44 (63.8%) underwent TA. Review of angiographic details revealed patients who underwent PDB had better pedal targets (inframalleolar/pedal score of P0 [24.0% vs 15.9%] or P1 [68.0% vs 61.3%]) than TA patients (inframalleolar/pedal score of P2 [22.7% vs 8.0%]).CONCLUSIONSPDB was associated with higher morbidity but better limb salvage than endovascular interventions. However, this could be explained by the association with better pedal targets in patients who underwent popliteal-tibial bypass. Prospective studies should be done comparing PDB and TA in cases with similar pedal targets.

01 Aug 2024·Archives of Microbiology

Platelet-derived biomaterial controls aspergillus fumigatus keratitis by decreasing fungal burden: an in vivo study

Article

Author: Rajaei, Elham ; Farahani, Abbas ; Shariati, Aref ; Hajihossein, Reza ; Hajian, Mohadeseh ; Moradabadi, Alireza ; Chegini, Zahra ; Didehdar, Mojtaba

Fungal keratitis is a severe corneal infection characterized by suppurative and ulcerative lesions. Aspergillus fumigatus is a common cause of fungal keratitis. Antifungal drugs, such as natamycin, are currently the first-line treatment for fungal keratitis, but their ineffectiveness leads to blindness and perforation. Additionally, the development of fungal resistance makes treating fungal keratitis significantly more challenging. The present study used platelet-derived biomaterial (PDB) to manage A. fumigatus keratitis in the animal model. Freezing and thawing processes were used to prepare PDB, and then A. fumigatus keratitis was induced in the mice. Topical administration of PDB, natamycin, and plasma was performed; quantitative real-time PCR (qPCR) and histopathologic examination (HE) were used to assess the inhibitory effect of the mentioned compounds against fungal keratitis. The qPCR results showed that PDB significantly decreased the count of A. fumigatus compared to the control group (P-value ≤ 5). Natamycin also remarkably reduced the count of fungi in comparison to the untreated animal, but its inhibitory effect was not better than PDB (P-value > 5). The findings of HE also demonstrated that treatment with PDB and natamycin decreased the fungal loads in the corneal tissue. However, plasma did not show a significant inhibitory effect against A. fumigatus. PDB is intrinsically safe and free of any infections or allergic responses; additionally, this compound has a potential role in decreasing the burden of A. fumigatus and treating fungal keratitis. Therefore, scientists should consider PDB an applicable approach to managing fungal keratitis and an alternative to conventional antifungal agents.

100 Deals associated with Prifinium Bromide

External Link

KEGG	Wiki	ATC	Drug Bank
D01377	Prifinium Bromide	A03AB18	DBSALT002516

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Spasm	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis